200 results on '"Weinhold, Kent"'
Search Results
2. Evaluation of host cellular responses to Epstein–Barr virus (EBV) in adult lung transplant patients with EBV‐associated diseases
3. Supplementary Figure 1 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
4. Supplementary Figure 7 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
5. Data from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
6. Figure S1 from Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma
7. Table S2 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
8. Figure S2 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
9. Figure S2 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
10. Table S1 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
11. Supplementary Figure 5 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
12. Supplementary Figure 3 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
13. Figure S1 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
14. Supplementary Figure 4 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
15. Table S1 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
16. Supplementary Figure 1 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
17. Figure S1 from Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma
18. Supplementary Figure 2 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
19. Table S1 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
20. Supplementary Figure 2 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
21. Supplementary Figure 3 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
22. Figure S2 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
23. Supplementary Table 1 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
24. Supplementary Figure 1 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
25. Figure S3 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
26. Table S3 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
27. Figure S2 from Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma
28. Figure S1 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
29. Figure S1 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
30. Supplementary Figure 6 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
31. Table S3 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
32. Figure S3 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
33. Supplementary Figure 7 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
34. Supplementary Figure 4 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
35. Supplementary Table 1 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
36. Figure S2 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
37. Figure S1 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
38. Supplementary Figure 3 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
39. Supplementary Figure 6 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
40. Supplementary Table 1 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
41. Data from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
42. Table S2 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
43. Supplementary Figure 2 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
44. Supplementary Figure 1 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
45. Table S1 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
46. Supplementary Table 2 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
47. Table S2 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
48. Figure S2 from Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma
49. Supplementary Figure 3 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
50. Supplementary Figure 5 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.